ArQule to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 15, 2019
May 08 2019 - 7:00AM
Business Wire
ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence,
President and Chief Operating Officer, and Dr. Marc Schegerin,
Chief Financial Officer and Head of Strategy, will present at the
Bank of America Merrill Lynch 2019 Health Care Conference on May
15, 2019 at 3:15 p.m. PT at the Encore Hotel in Las Vegas, NV.
The live webcast of the presentation will be available via the
“Investors & Media” section of ArQule’s website,
www.arqule.com, under “Events & Presentations.” A replay of the
webcast will be available shortly after the conclusion of the
presentation.
About ArQule
ArQule is a biopharmaceutical company engaged in the research
and development of targeted therapeutics to treat cancers and rare
diseases. ArQule’s mission is to discover, develop and
commercialize novel small molecule drugs in areas of high unmet
need that will dramatically extend and improve the lives of our
patients. Our clinical-stage pipeline consists of four drug
candidates, all of which are in targeted, biomarker-defined patient
populations, making ArQule a leader among companies our size in
precision medicine. ArQule’s pipeline includes: ARQ 531, an orally
bioavailable, potent and reversible dual inhibitor of both wild
type and C481S-mutant BTK, in phase 1 for patients with B-cell
malignancies refractory to other therapeutic options; miransertib
(ARQ 092), a potent and selective inhibitor of the AKT
serine/threonine kinase, planned to initiate registrational trial
cohorts in Proteus syndrome and PROS in 2019, and in phase 1b in
combination with the hormonal therapy, anastrozole, in patients
with advanced endometrial cancer; ARQ 751, a next generation highly
potent and selective AKT inhibitor, in phase 1 for patients with
AKT1 and PI3K mutations; and derazantinib, a multi-kinase inhibitor
designed to preferentially inhibit the fibroblast growth factor
receptor (FGFR) family, in a registrational trial for iCCA in
collaboration with Basilea and Sinovant. ArQule’s current discovery
efforts are focused on the identification and development of novel
kinase inhibitors, leveraging the Company’s proprietary library of
compounds.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190508005079/en/
Corporate Contact:Kathleen FarrenInvestor Relations
&Executive Assistant to the CFOir@arqule.com
Media Contact:Cait Williamson, Ph.D.LifeSci Public
Relations (646) 751-4366cait@lifescipublicrelations.com
www.ArQule.com
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Mar 2024 to Apr 2024
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Apr 2023 to Apr 2024